In 2018, LTS once again beat its previous records in terms of turnover, financial result, equity capital and liquidity. In line with the corporate strategy, the necessary investments into the expansion of structural and technical facilities were made.
Turnover: € 307 Mio.
R&D expenditures: 7,5 % of turnover
Investments: € 23 Mio.
Current number of patents: More than 300 patent families
Systems produced in 2018: > 840 Mio.
LTS conducted multiple active cooperation projects in 2018 with a large number of different partner companies from the pharmaceutical industry. These projects covered transdermal therapeutic systems (TTS), oral thin films (OTF) as well as Micro Array Patches (MAP).
The continuous evolution of existing LTS TTS and LTS OTF solutions, as well as innovations in new technology platforms such as microinvasive, transdermal systems or needle-free injection systems, are based on significant therapeutic requirements and market potential.